Current Problems in Cancer
Volume 29, Issue 5 , Pages 223-260 , September 2005

Current Issues in Wilms Tumor Management

  • Paul Grundy, MD (Professor and Director)

      Affiliations

    • Division of Hematology, Oncology and Palliative Care Department of Pediatrics University of Alberta Director of Pediatrics Cross Cancer Institute Edmonton, Canada
    • ,
  • Elizabeth Perlman, MD (Professor)

      Affiliations

    • Department of Pathology, Northwestern University’s Feinberg School of Medicine, Chicago, Illinois, USA
    • ,
  • Nancy S. Rosen, MD (Attending Radiologist)

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    • ,
  • Anne B. Warwick, MD, MPH (Assistant Professor)

      Affiliations

    • Pediatrics, Medical College of Wisconsin; Milwaukee, Wisconsin, USA
    • ,
  • Julia Glade Bender, MD (Assistant Professor of Clinical Pediatrics)

      Affiliations

    • Division of Pediatric Oncology, Columbia University, New York, New York, USA
    • ,
  • Peter Ehrlich, MD, MSc (Associate Professor)

      Affiliations

    • Pediatric Surgery Section, University of Michigan, Ann Arbor, Michigan, USA
    • ,
  • Fredric A. Hoffer, MD (FAAP, FSIR, Pediatric and Interventional Radiologist)

      Affiliations

    • Division of Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
    • ,
  • Nadine Deannie Lee, MD (Assistant Clinical Professor)

      Affiliations

    • Pediatric Hematology and Oncology, Indiana University, Bloomington, Indiana, USA
    • Corresponding Author InformationAddress correspondence to Paul Grundy, MD, 7330 Aberhart Centre One, 11402 University Ave, Edmonton AB T6G 2J3

References 

  1. Grundy PE , Green DM , Coppes MJ , Breslow NE , Ritchey ML , Perlman EJ , et al.   Renal tumors . In:  Pizzo PA ,  Poplack DG editor. Principles and Practice of Pediatric Oncology . Philadelphia, PA: Lippincott Williams & Wilkins; 2002;p. 865–893
  2. Shamberger RC , Guthrie KA , Ritchey ML , Haase GM , Takashima J , Beckwith JB , et al.   Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study-4 . Ann Surg . 1999;229(2):292–297
  3. Ehrlich P , Ritchey M , Hamilton T , Haase G , Ou S , Breslow N , et al.   Quality assessment for Wilms Tumor (a report from the National Wilms’ Tumor Study-5) . J Pediatr Surg . 2005;40:208–213
  4. Ritchey ML , Kelalis PP , Breslow N , Etzioni R , Evans I , Haase GM , et al.   Surgical complications after nephrectomy for Wilms tumor . Surg Gynecol Obstet . 1992;175:507–514
  5. Ritchey ML , Green DM , Thomas PRM , Smith GR , Haase G , Shochat S , et al.   Renal failure in Wilms’ tumor patients (a report from the National Wilms’ Tumor Study Group) . Med Pediatr Oncol . 1996;26:75–80
  6. Breslow NE , Takashima JR , Ritchey ML , Strong LC , Green DM . Renal failure in the Denys-Drash and Wilms; tumor-aniridia syndromes . Cancer Res . 2000;60(15):4030–4032
  7. Bonadio JF , Storer B , Norkool P , Farewell VT , Beckwith JB , D’Angio GJ . Anaplastic Wilms tumor (clinical and pathologic studies) . J Clin Oncol . 1985;3:513–520
  8. Faria P , Beckwith JB , Mishra K , Zuppa C , Weeks DA , Breslow N , et al.   Focal versus diffuse anaplasia in Wilms tumor - New definitions with prognostic significance . Am J Surg Pathol . 1996;20(8):909–920
  9. Beckwith JB . National Wilms Tumor Study (an update for pathologists) . Pediatr Dev Pathol . 1998;1:79–84
  10. Green DM , Breslow NE , Evans I , Moksness J , Finklestein JZ , Evans AE , et al.   The effect of chemotherapy dose intensity on the hematological toxicity of the treatment for Wilms’ tumor. A report of the National Wilms Tumor Study . Am J Pediatr Hematol Oncol . 1994;16:207–212
  11. Green DM , Breslow NE , Evans I , Moksness J , Finklestein JZ , Evans AE , et al.   Relationship between dose schedule and charges for treatment on National Wilms’ tumor Study-4. A report from the National Wilms’ Tumor Study Group . J Natl Cancer Inst Monogr . 1995;19:21–25
  12. Green DM , Breslow NE , Beckwith JB , Finklestein JZ , Grundy PE , Thomas PRM , et al.   Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms’ tumor (a report from the National Wilms’ tumor study group) . J Clin Oncol . 1998;16(1):237–245
  13. Green DM , Breslow NE , Beckwith JB , Finklestein JZ , Grundy P , Thomas PR , et al.   Effect of duration of treatment on treatment outcome and cost of treatment for Wilms’ tumor (a report from the National Wilms’ Tumor Study Group) . J Clin Oncol . 1998;16(12):3744–3751
  14. D’Angio GJ , Evans AE , Breslow N , Beckwith B , Bishop H , Feigl P , et al.   The treatment of Wilms’ tumor . Cancer . 1976;38:633–646
  15. D’Angio GJ , Evans A , Breslow N , Beckwith B , Bishop H , Farewell V , et al.   The treatment of Wilms’ Tumor (results of the Second National Wilms’ Tumor Study) . Am Cancer Soc . 1981;4:2302–2310
  16. Thomas PRM , Tefft M , Compaan PJ , Norkool P , Breslow NE , D’Angio GJ . Results of two radiotherapy randomizations in the Third National Wilms’ Tumor Study (NWTS-3) . Cancer . 1991;68:1703–1707
  17. Meisel JA , Guthrie KA , Breslow NE , Donaldson SS , Green DM . Significance and management of computed tomography detected pulmonary nodules (a report from the National Wilms Tumor Study Group) . Int J Radiat Oncol Biol Phys . 1999;44(3):579–585
  18. Green DM , Beckwith JB , Breslow NE , Faria P , Moksness J , Finklestein JZ , et al.   Treatment of children with stages II to IV anaplastic Wilms’ tumor (a report from the National Wilms’ Tumor Study Group) . J Clin Oncol . 1994;12(10):2126–2131
  19. Society of International Pediatric Oncology (SIOP) Wilms Tumor Protocol 2001.
  20. Green D , Grundy P , Shamberger R , Ritchey M . National Wilms Tumor Study Group V Protocol . 1995; https://members.childrensoncologygroup.org/Disc/surgery/surgicalHbooks.asp.
  21. McHugh K , Pritchard-Jones K . Problems in the imaging of three common paediatric solid tumours . Eur J Radiol . 2001;37:72–78
  22. D’Angio G , Rosenberg H , Sharples K , Kelalis P , Breslow NE , Green DM . Position paper: imaging methods for primary renal tumors of childhood: cost versus benefits . Med Ped Oncol . 1993;21:205–212
  23. Owens CM , Veys PA , Pritchard J , Levitt G , Imeson J , Dicks-Mireaux C . Role of chest computed tomography at diagnosis in the management of Wilms’ tumor (a study by the United Kingdom Children’s Cancer Study Group) . J Clin Oncol . 2002;20(12):2768–2773
  24. Ditchfield M , DeCampo J , Waters K , Nolan T . Wilms’ tumor (A rational use of preoperative imaging) . Pediatr Oncol . 1995;24:93–96
  25. Wootton-Gorges S , Albano EA , Riggs JM , Ihrke H , Rumack CM , Strain JD . Chest radiography versus chest CT in the evaluation for pulmonary metastases in pateints with Wilms tumor (a retrospective review) . Pediatr Radiol . 1999;30:533–539
  26. Cohen M , Smith WL , Weetman R , Provisor A . Pulmonary pseudometastases in children with malignant tumors . Radiology . 1981;141:371–374
  27. Ehrlich PF, Hamilton TE, Grundy P, et al. The value of surgery in directing therapy of Wilms tumor patients with pulmonary diseasse. A report from the National Wilms Tumor Study Group. J Pediatr Surg; in press.
  28. Wilimas JA , Kaste SC , Kauffman WM , Winer-Muran H , Morris R , Luo X , et al.   Use of chest computed tomography in the staging of pediatric Wilms’ tumor (interobserver variability and prognostic significance) . J Clin Oncol . 1997;15(7):2631–2635
  29. Attard-Monalto SP , Kingston JE , Eden OB , Plowman PN . Late follow-up of lung function after whole lung irradiation for Wilms’ tumour . The British J Radiol . 1992;66:1114–1118
  30. Green DM . Effects of treatment for childhood cancer on vital organ systems . Cancer . 2005;15:3299–3305
  31. Margrini S , Papi M , Bagnoli R , Dome JS , Bianchi S , Bitoun P . Late sequlae involving the breas after radiotherapy for lung metastases of Wilms tumor. Experience of the Florence radiotherapy and analysis of the literature . Radio Med (Torino) . 1995;89:865–869
  32. Paulino AC , Wen BC , Brown CK , Tannous R , Mayr NA , Zhen WK , et al.   Late effects in children treated with radiation therapy for Wilms tumor . Int J Rad Oncol . 2000;46:1239–1246
  33. Green DM , Breslow NE , Moksness J , D’Angio GJ . Congestive heart failure following initial therapy for Wilms tumor . AACR . 1998;161A
  34. Grosfeld JL . Risk-based management (current concepts of treating malignant solid tumors of childhood) . J Am Coll Surg . 1999;189(4):407–435
  35. Green DM , Nan B , Grigoriev Y , Takashima J , Norkool P , D’Angio GJ , et al.   Congestive heart failure (CHF) after treatment for Wilms tumor. A report from the National Wilms Tumor Study Group . 2002; Notes.
  36. Green DM , Grigoriev YA , Nan B , Takashima JR , Norkool PA , D’Angio GJ , et al.   Congestive heart failure after treatment for Wilms’ tumor (a report from the National Wilms’ Tumor Study Group) . J Clin Oncol . 2001;19(7):1926–1934
  37. Shearer P , Kapoor G , Beckwith JB . Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors (a reprot from the National Wilms Tumor Study Group) . J Pediatr Hematol Oncol . 2001;23:109–111
  38. Green DM . Use of chest computed tomography for staging and treatment of Wilms’ tumor in children . J Clin Oncol . 2002;20(12):2763–2764
  39. Green DM , Fernbach DJ , Norkool P , Kollia G , D’Angio GJ . The treatment of Wilms tumor patients with pulmonary metastases detected only with computed tomography (a report from the National Wilms Tumor Study) . J Clin Oncol . 1991;9:1776–1781
  40. Dirks A , Li S , Breslow N , Grundy P . Outcome of patients with lung metastases on NWTS 4 and 5 . Med Pediatr Oncol . 2003;41(4):251–252
  41. Wilimas JA , Douglass EC , Magil HL , Fitch S , Hustu HO . Significance of pulmonary computed tomography at diagnosis in Wilms’ tumor . J Clin Oncol . 1988;6:1144–1146
  42. Gylys-Morin V , Hoffer FA , Kozakewich H , Shamberger RC . Wilms tumor and nephroblastomatosis (imaging characteristics at gadolinium-enhanced MR imaging) . Radiology . 1993;188:517–521
  43. Cooper CS , Jaffe WI , Huff DS , Canning DA , Zderic SA , Meadows AT , et al.   The role of renal salvage procedures for bilateral Wilms tumor (a 15-year review) . J Urol . 2000;163:265–268
  44. Perlman E, Faria P, Hoffer FA, Sredni ST, Ritchey M, Shamberger RC, et al. Hyperplastic perilobar nephroblastosis: long-term survival of 52 patients. Pediatr Blood Cancer; in press.
  45. Garrett KM , Fuller C , Santana V , Shochat S , Hoffer FS . Percutaneous biopsy of pediatric solid tumors . Cancer . 2005;104(3):644–652
  46. Montgomery BT , Kelalis PP , Blute ML , Bergstrahl EJ , Beckwith JB , Norkool P , et al.   Extended follow up of bilateral Wilms’ tumor study (results of the National Wilms’ Tumor Study) . J Urol . 1991;146:514–518
  47. Ritchey ML , Kelalis PP , Haase GM , Schochat SJ , Green DM , D’Angio G . Preoperative therapy for intracaval and atrial extension of Wilms tumor . Cancer . 1993;71:4104–4110
  48. Ritchey ML , Green DM , Thomas P , Haase G , Shochat S . Accuracy of current imaging modalities in the diagnosis of synchronous bilateral Wilms’ tumor (a report from the National Wilms’ Tumor Study Group) . J Urol . 1994;151:329A
  49. Daw N , Kauffman W , Bodner S , Pratt C , Hoffer F . Patterns of abdominal relapse and role of sonography in Wilms tumor . Pediatr Hematol Oncol . 2002;19:107–115
  50. Slovis TL . Children, computed tomography radiation dose, and the As Low As Resonably Achievable (ALARA) concept . Pediatrics . 2003;112:971–972
  51. Rohrschneider W , Weirich A , Rieden K , Darge K , Troger J , Graf N . US, CT and MR imaging characteristics of nephroblastomatosis . Pediatr Radiol . 1998;28:435–443
  52. Ritchey M , Broecker B . Surgical complications following nephrectomy for Wilms tumor . Med Pediatr Oncol . 2003;41(4):251
  53. Dome JS , Liu T , Krasin M , Lott L , Shearer P , Daw NC , et al.   Improved survival for patients with recurrent Wilms tumor (the experience at St. Jude Children’s Research Hospital) . J Pediatr Hematol Oncol . 2002;24(3):192–198
  54. Grundy P , Breslow NE , Green DM , Sharples K , Evans A , D’Angio GJ . Prognostic factors of children with recurrent Wilms tumor (Results from the second and third National Wilms Tumor Study) . J Clin Oncol . 1989;7:638–647
  55. Tannous R , Giller G , Holmes E , Kim T , LaQuaglia M , Malogolowkin MM . Intensive therapy for high risk (HR) relapsed Wilms’ tumor (WT). A CCG-4921/POG-9445 study report . Proc ASCO . 2000;19:588a
  56. Abu-Ghosh AM , Krailo MD , Goldman SC , Slack RS , Davenport V , Morris E , et al.   Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor (a Children’s Cancer Group report) . Ann Oncol . 2002;13:460–469
  57. Weirich A , Ludwig R , Graf N , Abel U , Leuschner I , Vujanic G , et al.   Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity . Ann Oncol . 2004;15:808–820
  58. Marina NM , Rodman JH , Murry DJ , Shema SJ , Bowman LC , Jones DP , et al.   Phase I Study of escalating targeted doeses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors . J Natl Cancer Inst . 1994;86(7):544–548
  59. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertenstein M, et al  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele . Nature . 1996;380(6573):435–439
  60. Ferrara N , Carver-Moore K , Chen H , Dowd M , Lu L , O’Shea KS , et al.   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene . Nature . 1996;380(6573):439–442
  61. Ferrara N , Gerber H , LeCouter J . The biology of VEGF and its receptors . Nat Med . 2003;9(6):669–676
  62. Glade-Bender J , Kandel JJ , Yamashiro D . VEGF blocking therapy in the treatment of cancer . Expert Opin Biol . 2003;3(2):263–276
  63. Blann AD , Li JL , Li C , Kumar S . Increased serum VEGF in 13 children with Wilms’ tumour falls after surgery but rising levels predict poor prognosis . Cancer Lett . 2001;173:183–186
  64. Ghanem MA , van Steenbrugge GJ , Sudaryo MK , Mathoera RB , Nijman JM , van der Kwast H . Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma . J Clin Pathol . 2004;56:107–113
  65. Li W , Kessler P , Yeger H , Alami J , Reeve AE , Heathcott R , et al.   A gene expression signature for relapse of primary Wilms tumors . Cancer Res . 2005;65(7):2592–2601
  66. Davidoff AM , Nathwani AC , Spurbeck WW , Ng CY , Zhou J , Vanin EF . rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice . Cancer Res . 2002;62(11):3077–3083
  67. Rowe DH , Huang J , Kayton ML , Thompson R , Troxel A , O’Toole KM , et al.   Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms’ tumor . J Ped Surg . 2000;35(1):30–33
  68. Kim KJ , Li B , Winer J , Armanini M , Gillett N , Phillips HS , et al.   Inhibition of vascular endotherlial growth factor-induced angiogenesis suppresses tumor growth in vivo . Nature . 1993;362(6423):841–844
  69. Huang J , Moore J , Soffer S , Kim E , Rowe D , Manley CA , et al.   Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors . J Pediat Surg . 2001;36(2):357–361
  70. Frischer JS , Huang J , Serur A , Kadenhe-Chiweshe A , McCrudden KW , et al.   Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature . Int J Oncol . 2004;25(3):549–553
  71. Huang J , Frischer JS , Serur A , Kadenhe A , Yokoi A , McCrudden KW , et al.   Regression of established tumors and metastases by potent vascular endothelial growth factor blockade . Proc Natl Acad Sci USA . 2003;100(13):7785–7790
  72. Huang J , Soffer SZ , Kim S , McCrudden KW , Huang J , New T , et al.   Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis . Mol Can Res . 2004;2(1):36–42
  73. Soffer SZ , et al.   Combination antiangiogenic therapy (increased efficacy in a murine model of Wilms tumor) . J Pediatr Surg . 2001;36(8):1177–1181
  74. Ferrara N , Hillan KJ , Gerber HP , Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer . Nat Rev Drug Discov . 2004;3(5):391–400
  75. Gordon MS , Margolin K , Talpaz M , Sledge GW , Holmgren E , Benjamin R , et al.   Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer . J Clin Oncol . 2001;19(3):843–850
  76. Yang JC , Haworth L , Sherry RM , Hwu P , Schwartzentruber DJ , Topalian SL , et al.   A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer . N Engl J Med . 2003;349(5):843–850
  77. Spigel DR , et al.   bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC) (update of Phase II multicenter trial) . Proc Am Soc Clin Oncol . 2005;24:4540
  78. Motzer RJ , Amato R , Todd M , Hwu WJ , Cohen R , Baselga J , et al.   Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma . Invest New Drugs . 2003;21(1):99–101
  79. Drucker B , Bacik J , Ginsberg M , Marion S , Russo P , Mazumdar M , et al.   Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma . Invest New Drugs . 2003;21(3):341–345
  80. Yokoi A , McCrudden KW , Huang J , Kim ES , Soffer SZ , Frischer JS , et al.   Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms tumor . J Pediat Surg . 2003;38(11):1569–1573
  81. Borgstrom P , Gold DP , Hillan KJ , Ferrara N . Importance of VEGF for breast cancer angiogenesis in vivo (implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin) . Anticancer Res . 1999;19(5B):4203–4214
  82. Klement G , Baruchel S , Rak J , Man S , Clark K , Hicklin DJ , et al.   Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity . J Clin Invest . 2000;105(8):R15–R24
  83. Klement G . Differences in therapeutic indexes of combination metronomic chemotherapy and anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts . Clin Cancer Res . 2002;8(1):221–232
  84. Hurwitz H , Fehrenbacher L , Novotny W , Cartwright T , Hainsworth J , Heim W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350(23):2335–2342
  85. Kabbinavar F , Hurwitz HI , Fehrenbacher L , Meropol NJ , Novotny WF , Lieberman G , et al.   Phase II, randomized trail comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer . J Clin Oncol . 2003;21(1):60–65
  86. Santana V , Zamboni W , Gaijar A , Pappo A , Houghton P , Meyer W , et al.   Pharmacokinetically-guided use of topotecan (TPT), given (daily × 5) × 2, in children with relapsed solid tumors . Proc ASCO . 1997;16:511a
  87. Cosetti M , Wexler LH , Calleja E , Trippett T , LaQuaglia M , Huevos AG , et al.   Irinotecan for pediatric solid tumors (the Memorial Sloan-Kettering experience) . J Pediatr Hematol Oncol . 2002;24:101–105
  88. Pappo AS , et al.   Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS) (a Phase II window trail from the Soft Tussue Sarcoma Committee (STS) of the Children’s Oncology Group) . Proc Am Soc Clin Oncol . 2002;21
  89. Pratt C , et al.   Phase I study of oxaliplatin in pediatric patiens with malignant solid tumors . Proc Am Soc Clin Onc . 2001;20:
  90. Kausch I , Jiang H , Thode B , Doehn C , Kruger S , Jocham D . Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma . Eur Urol . 2005;47:703–709
  91. Thodtmann R , Sauter T , Weinknecht S , Weissbach L , Blatter J , Ohnmacht U , et al.   A phase II trial of pemetrexel in patients with metastatic renal cancer . Invest New Drugs . 2003;21:353–358
  92. Bardeesy N , Falkoff D , Petruzzi M-J , Nowak N , Zabel B , Adam M , et al.   Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations . Nat Genet . 1994;7:91–97
  93. Ghanem MA , van Steenbrugge GJ , Nijman RJ , van der Kwast TH . Prognostic markers in nephroblastma (Wilms’ tumor) . Urology . 2005;65:1047–1054
  94. Eggert A , Grotzer MA , Ikegaki N , Zhao H , Cnaan A , Brodeur GM . Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms tumor . J Clin Oncol . 2001;19(3):689–696
  95. Knezevich SR , Garnett MJ , Pysher TJ , Beckwith JB , Grundy PE , Sorensen PHB . ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma . Cancer Res . 1998;58:5046–5048
  96. Argani P , Ladanyi M . Recent advances in pediatric renal neoplasia . Adv Anat Path . 2003;10:243–260
  97. Safford SD , Freemerman AJ , Langdon S , Bentley R , Goyeau D , Grundy PE , et al.   Decreased e-cadherin expression correlates with higher stage of Wilms’ tumors . J Pediatr Surg . 2005;40:341–348
  98. Dome JS , Chung S , Bergemann T , Umbricht CB , Saji M , Carey LA , et al.   High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms’ tumor . Cancer Res . 1999;59:4301–4307
  99. Williams RD , Hing SN , Greer BT , Whiteford CC , Wei JS , Natrajan R , et al.   Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines . Genes Chromosomes Cancer . 2004;41(1):65–79
  100. Li W , Kessler P , Yeger H , Alami J , Reeve AE , Heathcott R , et al.   A gene expression signature for relapse of primary Wilms Tumors . Cancer Res . 2005;65:2592–2601
  101. Li W , Kessler P , Yerger H , Alami J , Reeve A , Heathcott R , et al.   A gene epression signature for relapse of primary Wilms Tumors . Cancer Res . 2005;65(7):2592–2601
  102. Takahashi M , Yang XJ , Lavery TT , Furge KA , Williams BO , Tretiakova M , et al.   Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features . Cancer Res . 2002;62(22):6598–6605

PII: S0147-0272(05)00054-1

doi: 10.1016/j.currproblcancer.2005.08.002

Current Problems in Cancer
Volume 29, Issue 5 , Pages 223-260 , September 2005

Article Tools

* Image Usage & Resolution